Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Has announcements × GRN163L peptide × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Myelodysplastic Syndromes 1

Interventions

umbralisib 1 ublituximab 1 relatlimab 1 pembrolizumab 1 palbociclib 1 inavolisib 1 imetelstat 1 Pemetrexed 1 Nivolumab 1 GRN163L peptide 1 Fulvestrant 1 Emapalumab 1 Cisplatin 1 Bendamustine Hydrochloride 1 ALT-803 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02598661 2026-01-05

Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Geron Corporation

Phase 2/3 Active not recruiting

289 enrolled 35 charts 1 FDA

Myelodysplastic Syndromes, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡